HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model‐based cost‐effectiveness

Abstract We evaluated the cost‐effectiveness of HPV16/18 vaccination for girls aged 12 years in The Netherlands in addition to cervical cancer screening. For this purpose, we developed a simulation model that describes the relation between each of the high‐risk human papillomavirus (hrHPV) types and cervical disease, allowing the occurrence of multiple type‐specific infections. Model parameters were derived from Dutch cohort studies, including a large population‐based screening trial, and from the national cervical cancer registry. The model satisfactorily reproduced Dutch data on HPV infectio... Mehr ...